Seventy-nine patients with soft-tissue sarcomas and eight with sarcomas of bone and cartilage were perfused using melphalan and dactinomycin. Almost half of the patients had liposarcoma or unclassified sarcoma and one fifth had fibrosarcoma or a synovial sarcoma. Thirty-eight percent of the patients received prior therapies and had local recurrences. Six percent of patients had distant metastasis. The five-year survival rate was 57% and the ten-year rate 45%. Fifty-nine percent were free of disease at two years and 9% had developed local recurrences by then. There was one surgical death in this series.
Perfusion treats the region of involvement by soft-tissue sarcomas and thus reduces the surgical resection necessary to obtain disease control. It is not recommended for sarcomas arising from bone or cartilage.
McBride CM. Sarcomas of the Limbs: Results of Adjuvant Chemotherapy Using Isolation Perfusion. Arch Surg. 1974;109(2):304–308. doi:10.1001/archsurg.1974.01360020164032
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: